Your browser doesn't support javascript.
loading
Association with the nonparoxysmal atrial fibrillation duration and outcome of ExTRa Mapping-guided rotor ablation.
Okuyama, Yusuke; Ozawa, Tomoya; Nishikawa, Takuma; Fujii, Yusuke; Kato, Koichi; Sugimoto, Yoshihisa; Nakagawa, Yoshihisa; Ashihara, Takashi.
Afiliación
  • Okuyama Y; Department of Cardiovascular Medicine Shiga University of Medical Science Otsu Japan.
  • Ozawa T; Department of Cardiovascular Medicine Shiga University of Medical Science Otsu Japan.
  • Nishikawa T; Department of Cardiovascular Medicine Shiga University of Medical Science Otsu Japan.
  • Fujii Y; Department of Cardiovascular Medicine Shiga University of Medical Science Otsu Japan.
  • Kato K; Department of Cardiovascular Medicine Shiga University of Medical Science Otsu Japan.
  • Sugimoto Y; Department of Cardiovascular Medicine Shiga University of Medical Science Otsu Japan.
  • Nakagawa Y; Department of Medical Informatics and Biomedical Engineering Shiga University of Medical Science Otsu Japan.
  • Ashihara T; Department of Cardiovascular Medicine Shiga University of Medical Science Otsu Japan.
J Arrhythm ; 39(4): 531-538, 2023 Aug.
Article en En | MEDLINE | ID: mdl-37560288
ABSTRACT

Background:

Additional ablation strategies after pulmonary vein isolation (PVI) for patients with nonparoxysmal atrial fibrillation (non-PAF) lasting ≥2 years have not been fully effective. This is presumably because of insufficient identification of non-PAF maintenance mechanisms. In this study, we employed a novel online and real-time phase mapping system, ExTRa Mapping, to identify and modulate rotors as one of the non-PAF maintenance mechanisms in patients with non-PAF sustained after PVI. We investigated the relationship between outcomes of ExTRa Mapping-guided rotor ablation (ExTRa-ABL) and non-PAF duration prior to this procedure.

Methods:

This study consisted of 73 non-PAF patients (63 ± 8 years, non-PAF duration 31 ± 37 months) who underwent the first ExTRa-ABL in patients with non-PAF sustained after completion of PVI.

Results:

Freedom from non-PAF/atrial tachycardia (AT) recurrence at 12 months after ExTRa-ABL was achieved in 50 (69%) of patients. The non-PAF duration prior to ExTRa-ABL was significantly longer in patients with non-PAF/AT recurrence after ExTRa-ABL compared with those without (56 ± 50 vs. 19 ± 22 months, p = .001). In patients with non-PAF duration of ≤60 months prior to ExTRa-ABL, compared with >60 months, non-PAF/AT-free rate was significantly higher (68.9% vs. 23.1%, p < .001), during the follow-up of 36 ± 18 months.

Conclusions:

A non-PAF duration of ≤60 months prior to ExTRa-ABL was associated with a better outcome. The effect of ExTRa-ABL was considered to be limited in patients with >60 months of non-PAF duration.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Risk_factors_studies Idioma: En Revista: J Arrhythm Año: 2023 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Risk_factors_studies Idioma: En Revista: J Arrhythm Año: 2023 Tipo del documento: Article
...